U.S. lawmakers attempting to cut the cost of insulin for more than a million Americans to $35 per month are unlikely to succeed as November elections draw near and complicate bipartisan support, health policy and political experts say.
The U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb’s oral heart disease drug, making Camzyos (mavacamten) the first cardiac myosin inhibitor to be permitted for use in the country.
On Thursday, members of both the U.S. House of Representatives and the U.S. Senate introduced legislation that targets efforts that have limited competition, which keeps the price of prescription drugs high.
U.S. Senate Majority Leader Chuck Schumer said on March 22 he intends to hold votes this spring on a bill that would cap the cost of insulin, a life-sustaining diabetes drug.
EVERSANA, a pioneer of next generation commercial services to the global life sciences industry, unveiled NAVLIN by EVERSANA™, a new, comprehensive ecosystem of price and access solutions to help established and emerging pharmaceutical companies navigate global market access complexities. NAVLIN combines best-in-class data, software and insights into an integrated platform, backed by a team of innovative industry experts.
Martin Shkreli received his second lifetime ban from the pharmaceutical industry. One month after U.S. District Court Judge Denise Cotes banned the “Pharma Bro” from future involvement in the industry, a second judge handed down a similar order and ordered him to pay a $1.39 million fine.
U.S. President Joe Biden on February 10 said he expected inflation to start to ease during 2022 as supply chain logjams clear up, while saying his administration was already helping ease shortages, as new data showed the biggest jump in consumer prices in 40 years.
Gilead Sciences Inc.’s COVID-19 drug remdesivir during 2021 overtook AbbVie Inc.’s 20-year-old arthritis drug Humira as the medicine that U.S. hospitals spent the most on, according to Vizient Inc., a purchasing group used by about half the nation’s hospitals.
As 2022 unfolds, pharmaceutical companies were quick to implement price increases on hundreds of prescription medications. According to research company 46brooklyn, drug manufacturers raised prices on 460 different medicines in the first days of January.
Biogen announced that effective January 1, 2022, the company will cut the wholesale acquisition cost of the Alzheimer’s drug Aduhelm (aducanumab) in half.